Long Acting Anti Vegf Formulations Growth Index

Long Acting Anti Vegf Formulations Growth Index | Source: Fact.MR

Share




Country
CAGR (2026-2036)


United States
17.7%


China
15.6%


France
13.5%


Germany
13.4%


Japan
12.9%

Source: Fact.MR analysis. Updated Nov 19, 2026

Source: Fact.MR analysis.

Why is the United States the fastest-growing market for long-acting anti-VEGF formulations?

Demand for long-acting anti-VEGF formulations in the United States is forecast to increase at a 17.7% CAGR through 2036, the fastest among the five countries.

Long Acting Anti Vegf Formulations Forecast Usa

Long Acting Anti Vegf Formulations Forecast Usa | Source: Fact.MR

Share

Available therapies, including Eylea HD, Vabysmo and Susvimo, provide treatment options with extended dosing intervals or sustained drug delivery. Pharmaceutical companies are also advancing longer-acting candidates through clinical development. Retina specialists are examining treatments that reduce frequent clinic visits while maintaining disease control. Further adoption will depend on clinical safety, treatment durability, insurance coverage and patient outcomes across retinal diseases.

What is driving long-acting anti-VEGF demand in China?

Sales of long-acting anti-VEGF formulations in China are set to rise at a 15.6% CAGR through 2036, supported by the country’s substantial diabetic population and increasing retinal disease treatment needs.

National reimbursement coverage for anti-VEGF medicines, including conbercept, supports patient access to established therapies. Ophthalmology providers are examining longer treatment intervals to manage clinic workloads and improve patient convenience. Pharmaceutical manufacturers are developing sustained-delivery approaches for retinal conditions. Commercial uptake will reflect reimbursement eligibility, clinical effectiveness, treatment costs and access to specialized ophthalmology services.

What is shaping long-acting anti-VEGF demand in France?

Demand for long-acting anti-VEGF formulations in France is likely to advance at a 13.5% CAGR through 2036 as retina specialists adopt treatments offering extended dosing intervals.

Faricimab and aflibercept 8 mg provide options for managing retinal diseases with fewer injections in suitable patients. Limited ophthalmologist availability in rural areas is also increasing interest in reducing routine clinic visits. Healthcare providers are assessing treatment durability alongside visual outcomes and patient safety. Prescribing decisions will reflect clinical guidelines, reimbursement conditions and individual responses to anti-VEGF therapy.

What is shaping long-acting anti-VEGF demand in Germany?

Demand for long-acting anti-VEGF formulations in Germany is forecast to expand at a 13.4% CAGR through 2036, supported by the availability of extended-interval retinal therapies.

Leverkusen-based Bayer markets aflibercept 8 mg in Europe, providing ophthalmologists with another treatment option for eligible patients. The introduction of aflibercept biosimilars has also increased pricing competition across conventional anti-VEGF therapies. Retina clinics are examining treatment schedules that balance patient convenience with disease control. Manufacturers will compete through clinical evidence, dosing flexibility, reimbursement access and demonstrated treatment durability.

Why is long-acting anti-VEGF growth slower in Japan?

Demand for long-acting anti-VEGF formulations in Japan is expected to increase at a 12.9% CAGR through 2036, the slowest among the five countries.

Regular pharmaceutical price revisions influence revenue growth and commercial planning for retinal treatments. Chugai Pharmaceutical, part of the Roche Group, markets faricimab in Japan, supporting access to extended-interval anti-VEGF therapy. Ophthalmologists are evaluating longer dosing schedules for patients requiring repeated retinal injections. Further adoption will depend on treatment effectiveness, patient safety, reimbursement pricing and evidence supporting reduced injection frequency.